Alnylam Pharmaceuticals Inc. (ALNY) said it has initiated a Phase 1 clinical trial with ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin or TTR-mediated amyloidosis (ATTR amyloidosis).
from RTT - Biotech http://ift.tt/1PLhXPW
via IFTTT
No comments:
Post a Comment